Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDPK1 | O15530 | 1/20 | 0.36 |
| ▸ | MTOR | P42345 | 1/20 | 0.36 |
| ▸ | TNF | P01375 | 1/20 | 0.35 |
| ▸ | LGALS8 | O00214 | 1/20 | 0.33 |
| ▸ | NEU3 | Q9UQ49 | 2/20 | 0.32 |
| ▸ | BCHE | P06276 | 2/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.31 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.30 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.30 |
| ▸ | FGF2 | P09038 | 1/20 | 0.30 |
| ▸ | MDK | P21741 | 1/20 | 0.30 |
| ▸ | ABCB1 | P08183 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1971069 | 0.90 | PDPK1 (0.39) | PDPK1MTORTNFLGALS8ALDH1A1 | |
| SCHEMBL1491923 | 0.84 | FGF2 (0.43) | PDPK1MTORLGALS8BCHEALDH1A1 | |
| SCHEMBL1491920 | 0.83 | FGF2 (0.31) | PDPK1MTORFGF2MDK | |
| SCHEMBL30689829 | 0.78 | SSTR5 (0.42) | — | |
| SCHEMBL2804636 | 0.77 | PDPK1 (0.43) | PDPK1MTORALDH1A1CYP2C9CYP2C19 | |
| SCHEMBL13129921 | 0.77 | PDPK1 (0.43) | PDPK1MTORALDH1A1CYP2C9CYP2C19 | |
| SCHEMBL17557897 | 0.76 | PDPK1 (0.36) | PDPK1MTORNEU3ALDH1A1CYP2C9 | |
| SCHEMBL21195773 | 0.73 | PDPK1 (0.36) | PDPK1MTORNEU3ALDH1A1CYP2C9 | |
| SCHEMBL1973526 | 0.73 | PDPK1 (0.34) | PDPK1MTORLGALS8BCHEALDH1A1 | |
| SCHEMBL25365555 | 0.73 | PDPK1 (0.47) | PDPK1MTORTNFBCHEALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7901687-B2 | Antibodies for the detection of Bacillus anthracis and vaccine against B. anthracis infections | ETH ZURICH (CH) | 2011-03-08 | — | — | US | disclosed |
| US-20090155299-A1 | Antibodies for the Detection of Bacillus Anthracis and Vaccine Against B. Anthracis Infections | SCHWEIZERISCHES TROPENINSTITUT (CH) | 2009-06-18 | — | — | US | disclosed |
| EP-2012821-A2 | ANTIBODIES FOR THE DETECTION OF BACILLUS ANTHRACIS AND VACCINE AGAINST B. ANTHRACIS INFECTIONS | ETH Zürich (CH) | 2009-01-14 | — | — | EP | disclosed |
| WO-2007125089-A2 | ANTIBODIES FOR THE DETECTION OF BACILLUS ANTHRACIS AND VACCINE AGAINST B. ANTHRACIS INFECTIONS | ETH Zürich (CH) | 2007-11-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090155299-A1 | Antibodies for the Detection of Bacillus Anthracis and Vaccine Against B. Anthracis Infections | ANTXR2, CERT1, DAD1 | PDPK1 4713/4885MTOR 4359/4885TNF 1394/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.